News & publications
Progress, on the record.
Three peer-reviewed papers, an independent replication, and a steady cadence of presentations and milestones on the path to the clinic.
Publications
Peer-reviewed science.
Antibody Therapeutics · 2026
Cytotoxic activity and safety characterization of IMV-M™, a MUC16 × DR5 bispecific antibody
Read →Nature Scientific Reports · 2025
A bispecific anti-MUC16/anti-DR5 antibody achieves effective, tumor-selective DR5-mediated tumor regression
Read →Antibody Therapeutics · 2024
Beyond ADCs: harnessing bispecific antibodies to directly induce apoptosis for targeted tumor eradication
Read →Timeline
News & milestones
2026
Sep 2026 · upcoming
Event
ImmuVia to speak at the 17th World Bispecific Summit, Boston
Iosif Gershteyn joins the speaker faculty (September 15–17, Boston, MA).
Read →Jun 2026 · upcoming
Event
Panel: the preclinical-to-clinical translational gap
Iosif Gershteyn on a panel convened by Locust Walk and Axella Biosciences.
May 2026
Publication
Cytotoxic activity and safety characterization of IMV-M™ published in Antibody Therapeutics
Peer-reviewed in Oxford University Press's Antibody Therapeutics: shed CA125 does not neutralize IMV-M™, and anti-drug antibodies do not drive off-target hepatotoxicity.
Read →Apr 2026
Presentation
IMV-M™ data presented at the AACR Annual Meeting 2026
A poster detailing continued progress on the MUC16×DR5 bispecific.
2026
Mar 2026
Publication
Preprint of the IMV-M™ mechanism & safety study released
The integrated cytotoxicity and safety dataset for IMV-M™ made available ahead of peer review.
2025
Nov 2025
Event
ImmuVia presents at the 24th BioPharma Drug Discovery Nexus
“Beyond ADCs: Cancerlysins™ — Bispecific Apoptosis Triggers” (Parsippany, New Jersey).
Nov 2025
Presentation
Dr. Goldmacher presents new IMV-M™ data at PEGS Europe, Lisbon
Oct 2025
Collaboration
Collaboration with TGen, part of City of Hope
An independent, foundation-funded study replicated IMV-M™'s anti-tumor efficacy.
Oct 2025
Recognition
ImmuVia presents at the TMCi Accelerator for Cancer Therapeutics (ACT) Summit
Aug 2025
Jul 2025
Event
ImmuVia presents at the Aging Code Summit (Portal Innovations)
Jun 2025
Presentation
Dr. Goldmacher presents Cancerlysin IMV-M™ at PEGS Boston 2025
Mar 2025
Publication
Breakthrough IMV-M™ results published in Nature Scientific Reports
A bispecific anti-MUC16/anti-DR5 antibody achieves effective, tumor-selective DR5-mediated tumor regression.
Read →Mar 2025
Presentation
ImmuVia presents IMV-M™ data at the IO360° Biotech Showcase, Boston
Jan 2025
Jan 2025
Award
ImmuVia selected for the Texas Medical Center 2025 Accelerator for Cancer Therapeutics (ACT)
Read →2024
Oct 2024
Publication
Beyond ADCs: harnessing bispecific antibodies to directly induce apoptosis
Published in Antibody Therapeutics (Oxford University Press).
Read →2024
Presentation
In vivo Cancerlysin™ IMV-M™ data presented at the Gordon Research Conference
2024
Announcement
ImmuVia exits stealth at PEGS 2024; John Lambert, PhD joins the Scientific Advisory Board
2023
2023
Patent
IMV-M™ patent application filed (PCT)
Extensive composition and method claims sought across major jurisdictions.
2023
Media
Novel approach to cancer treatment via selective apoptosis — interview with Dr. Goldmacher